Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9973) 9973
Publication (886) 886
Book / eBook (672) 672
Book Review (128) 128
Conference Proceeding (45) 45
Book Chapter (37) 37
Magazine Article (22) 22
Dissertation (10) 10
Government Document (6) 6
Data Set (1) 1
Newsletter (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9101) 9101
female (5638) 5638
oncology (4517) 4517
index medicus (4305) 4305
male (3555) 3555
cancer (2890) 2890
breast cancer (2748) 2748
animals (2737) 2737
neoplasms, hormone-dependent - drug therapy (2356) 2356
middle aged (2301) 2301
breast neoplasms - drug therapy (2196) 2196
aged (1887) 1887
breast neoplasms - pathology (1677) 1677
prostate cancer (1535) 1535
cell line, tumor (1517) 1517
adult (1492) 1492
breast neoplasms - metabolism (1440) 1440
neoplasms, hormone-dependent - pathology (1393) 1393
prostatic neoplasms - drug therapy (1367) 1367
mice (1360) 1360
prostatic neoplasms - pathology (1279) 1279
tumors (1214) 1214
expression (1205) 1205
research (1189) 1189
estrogen (1129) 1129
antineoplastic agents, hormonal - therapeutic use (1090) 1090
neoplasms, hormone-dependent - metabolism (1072) 1072
prognosis (1057) 1057
care and treatment (1022) 1022
apoptosis (963) 963
medicine & public health (931) 931
tamoxifen (906) 906
breast neoplasms - genetics (902) 902
carcinoma (890) 890
health aspects (888) 888
prostatic neoplasms - metabolism (840) 840
risk factors (839) 839
endocrinology & metabolism (821) 821
postmenopausal women (812) 812
therapy (812) 812
chemotherapy (793) 793
receptors, estrogen - metabolism (756) 756
aged, 80 and over (745) 745
breast-cancer (737) 737
gene expression (727) 727
neoplasms, hormone-dependent - therapy (723) 723
metastasis (722) 722
treatment outcome (721) 721
growth (698) 698
analysis (692) 692
gene expression regulation, neoplastic (691) 691
tamoxifen - therapeutic use (686) 686
antineoplastic agents - therapeutic use (684) 684
tumor cells, cultured (681) 681
biochemistry & molecular biology (675) 675
cell biology (675) 675
medicine (661) 661
signal transduction (651) 651
genetic aspects (620) 620
immunohistochemistry (603) 603
prostatic neoplasms - genetics (596) 596
antineoplastic agents - pharmacology (592) 592
development and progression (591) 591
cell proliferation - drug effects (586) 586
neoplasms (580) 580
urology & nephrology (565) 565
article (561) 561
neoplasms, hormone-dependent - genetics (561) 561
cells (553) 553
rats (550) 550
research article (547) 547
apoptosis - drug effects (544) 544
proteins (543) 543
gene-expression (531) 531
antineoplastic combined chemotherapy protocols - therapeutic use (524) 524
mice, nude (509) 509
androgen receptor (505) 505
androgens (505) 505
neoplasm staging (496) 496
risk (493) 493
estrogens (492) 492
physiological aspects (490) 490
aromatase inhibitors (489) 489
cell proliferation (487) 487
pharmacology & pharmacy (481) 481
women (479) 479
neoplasm metastasis (470) 470
estrogen-receptor (469) 469
hormones (468) 468
drug therapy (465) 465
disease progression (464) 464
endocrine therapy (463) 463
receptors, androgen - metabolism (462) 462
survival (455) 455
breast (453) 453
receptors, estrogen - analysis (452) 452
chemotherapy, adjuvant (435) 435
prostatic neoplasms - therapy (431) 431
breast neoplasms - therapy (428) 428
combined modality therapy (428) 428
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (556) 556
Collection Dvlpm't (Acquisitions) - Closed Orders (38) 38
Collection Dvlpm't (Acquisitions) - Vendor file (17) 17
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (17) 17
Online Resources - Online (13) 13
Humber River Regional Hospital - Finch Stacks (9) 9
Scarborough Hospital - Birchmount (7) 7
Scarborough Hospital - General (7) 7
St. Michael's Hospital - Stacks (7) 7
Humber River Regional Hospital - Church Stacks (6) 6
Markham Stouffville Hospital - Stacks (6) 6
Lakeridge Health Sciences - Oshawa (5) 5
UofT at Mississauga - Stacks (5) 5
Mt Sinai Hospital - Pathology (4) 4
Providence Healthcare - Stacks (4) 4
Chemistry (A D Allen) - Stacks (3) 3
Credit Valley Hospital - Stacks (3) 3
Gerstein Science - Circulation Desk (3) 3
New College (Ivey) - Stacks (2) 2
OISE - Stacks (2) 2
St Josephs Health Centre - Stacks (2) 2
Trillium Health Centre - Stacks (2) 2
UofT at Scarborough - Stacks (2) 2
Credit Valley Hospital - Special Collections (1) 1
Gerstein Science - Not Returned (1) 1
Gerstein Science - Reference (1) 1
Humber River Regional Hospital - Church Reference (1) 1
Markham Stouffville Hospital - Storage (1) 1
Physics - Stacks (1) 1
Toronto East General Hospital - Missing (1) 1
Toronto East General Hospital - Online (1) 1
Toronto East General Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10189) 10189
German (159) 159
Japanese (136) 136
French (116) 116
Spanish (55) 55
Russian (52) 52
Italian (31) 31
Chinese (14) 14
Hungarian (11) 11
Polish (7) 7
Serbian (5) 5
Czech (4) 4
Ukrainian (4) 4
Dutch (3) 3
Swedish (3) 3
Croatian (2) 2
Finnish (2) 2
Hebrew (2) 2
Portuguese (2) 2
Turkish (2) 2
Arabic (1) 1
Bulgarian (1) 1
Danish (1) 1
Korean (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Gender‐affirming hormone therapy and the risk of sex hormone‐dependent tumours in transgender individuals—A systematic review
by McFarlane, Thomas and Zajac, Jeffrey D and Cheung, Ada S
Clinical Endocrinology, ISSN 0300-0664, 12/2018, Volume 89, Issue 6, pp. 700 - 711
Summary Background Cancers are a leading cause of death worldwide, and transgender individuals are no exception. The effects of gender‐affirming hormone... 
transgender persons | testosterone | hormones | review | oestradiol | gender dysphoria | neoplasms | MORTALITY | PROLACTIN | FEMALE | TRANSSEXUALS RECEIVING TREATMENT | BREAST-CANCER RISK | MENINGIOMA | PROSTATE-CANCER | ENDOCRINOLOGY & METABOLISM | CYPROTERONE-ACETATE | ESTROGEN | PATIENT | Estradiol - adverse effects | Transgender Persons - statistics & numerical data | Testosterone - adverse effects | Neoplasms, Hormone-Dependent - etiology | Humans | Testosterone | Transgender people | Oncology, Experimental | Mortality | Research | Gender identity | Cancer | Tumors | Prolactin | Pituitary | Case reports | Endocrine therapy | Systematic review | Adenoma | Transgender persons | Meningioma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Androgen receptors in hormone-dependent and castration-resistant prostate cancer
by Shafi, Ayesha A and Yen, Aihua E and Weigel, Nancy L
Pharmacology and Therapeutics, ISSN 0163-7258, 2013, Volume 140, Issue 3, pp. 223 - 238
In the United States, prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in males and the second leading cause of cancer-related death... 
Castration-resistant prostate cancer | Steroidogenesis | Abiraterone | Prostate | Enzalutamide (MDV3100) | Androgen receptor | TRANSCRIPTION FACTORS | SIGNALING PATHWAYS | REGULATED GENE-EXPRESSION | CELL-PROLIFERATION | SPLICE VARIANTS | RADIATION-THERAPY | MITOXANTRONE PLUS PREDNISONE | GROWTH-FACTOR-BETA | PHARMACOLOGY & PHARMACY | LIGAND-BINDING DOMAIN | HISTONE DEACETYLASE INHIBITORS | Androgens - genetics | Animals | Receptors, Androgen - genetics | Humans | Receptors, Androgen - metabolism | Male | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androgens - metabolism | Prostatic Neoplasms, Castration-Resistant - metabolism | Prostatic Neoplasms, Castration-Resistant - genetics | Proteins | Physiological aspects | Hormones, Sex | Prostate cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Polymer Therapeutics Designed for a Combination Therapy of Hormone‐Dependent Cancer
by Vicent, María J and Greco, Francesca and Nicholson, Robert I and Paul, Alison and Griffiths, Peter C and Duncan, Ruth
Angewandte Chemie International Edition, ISSN 1433-7851, 06/2005, Volume 44, Issue 26, pp. 4061 - 4066
Designer drug: A polymer therapeutic was designed for a combination therapy of breast cancer. N‐(2‐Hydroxypropyl)methacrylamide was used as the model polymer... 
tumor targeting | drug delivery | polymers | drug design | antitumor agents | Drug delivery | Drug design | Antitumor agents | Polymers | Tumor targeting | DOXORUBICIN | CHEMISTRY, MULTIDISCIPLINARY | ENZYME PRODRUG THERAPY | BREAST-CANCER | MACROMOLECULAR THERAPEUTICS | MODEL COMBINATION | IN-VITRO | DRUG-CARRIER | CONJUGATE | AROMATASE INHIBITORS | COPOLYMER | Aminoglutethimide - pharmacology | Antibiotics, Antineoplastic - pharmacology | Humans | Doxorubicin - chemistry | Methacrylates - chemistry | Aminoglutethimide - analogs & derivatives | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - chemistry | Doxorubicin - analogs & derivatives | Drug Design | Polymers - pharmacology | Cell Line, Tumor | Inhibitory Concentration 50 | Methacrylates - pharmacology | Female | Polymers - chemistry | Molecular Structure | Neoplasms, Hormone-Dependent - drug therapy | Drug Therapy, Combination | Aminoglutethimide - chemistry | Doxorubicin - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies
by Byrns, Michael C and Steckelbroeck, Stephan and Penning, Trevor M
Biochemical Pharmacology, ISSN 0006-2952, 2008, Volume 75, Issue 2, pp. 484 - 493
Aldo-keto reductase (AKR) 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase) regulates ligand access to steroid hormone and prostaglandin... 
Prostaglandin metabolism | Inhibitor design | Steroid hormone metabolism | Cancer treatment | NSAIDs | Chemoprevention | cancer treatment | ANDROGEN RECEPTOR | SIGNALING PATHWAYS | INCREASED EXPRESSION | CRYSTAL-STRUCTURE | prostaglandin metabolism | 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J | PROLIFERATOR-ACTIVATED RECEPTOR | 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE | chemoprevention | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACID-BINDING PROTEIN | CYCLOOXYGENASE-2 INHIBITORS | inhibitor design | PHARMACOLOGY & PHARMACY | steroid hormone metabolism | Indomethacin - analogs & derivatives | Oxidation-Reduction | Humans | Enzyme Inhibitors - pharmacology | Hydroxyprostaglandin Dehydrogenases - metabolism | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Melatonin - analogs & derivatives | Aldo-Keto Reductase Family 1 Member C3 | 3-Hydroxysteroid Dehydrogenases - metabolism | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Catalysis | Neoplasms, Hormone-Dependent - drug therapy | Melatonin - pharmacology | Phenanthrenes - metabolism | Dihydrotestosterone - metabolism | Enzymes | Care and treatment | Synthetic prostaglandins F | Crystals | Hormones | Organic acids | Heterocyclic compounds | Physiological aspects | Glycols | Hormones, Sex | Indomethacin | Structure | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer
by Mo, Zhiqiang and Liu, Manran and Yang, Fangfang and Luo, Haojun and Li, Zhenhua and Tu, Gang and Yang, Guanglun
Breast Cancer Research, ISSN 1465-5411, 11/2013, Volume 15, Issue 6, pp. R114 - R114
Introduction: Tamoxifen is widely used to treat hormone-dependent breast cancer, but its therapeutic benefit is limited by the development of drug resistance.... 
KINASE INHIBITOR GEFITINIB | ENDOCRINE RESISTANCE | GROWTH-FACTOR RECEPTOR | ONCOLOGY | PROTEIN-COUPLED RECEPTOR | ACQUIRED-RESISTANCE | GENE-EXPRESSION | MEMBRANE-RECEPTOR | LONG-TERM TREATMENT | ESTROGEN-RECEPTOR | ER-ALPHA | Neoplasms, Hormone-Dependent - metabolism | Receptors, Estrogen - metabolism | Receptors, G-Protein-Coupled - metabolism | Humans | Middle Aged | Receptors, G-Protein-Coupled - agonists | Quinolines - pharmacology | Breast Neoplasms - metabolism | MCF-7 Cells | Aged, 80 and over | Adult | Female | Cyclic AMP - metabolism | Estradiol - pharmacology | ErbB Receptors - metabolism | Receptors, Estrogen - genetics | Antineoplastic Agents, Hormonal - pharmacology | Receptors, Estrogen - antagonists & inhibitors | Breast Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Breast Neoplasms - pathology | Mice, Nude | Neoplasms, Hormone-Dependent - pathology | Receptors, G-Protein-Coupled - antagonists & inhibitors | Tamoxifen - pharmacology | Aged | Receptors, G-Protein-Coupled - genetics | Neoplasms, Hormone-Dependent - drug therapy | Benzodioxoles - pharmacology | Drug Resistance, Neoplasm - drug effects | Breast cancer | Cyclic adenylic acid | Research | Metastasis | G proteins | Tamoxifen | Gene expression | Estradiol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy
by Ning, Xiaohui and Yang, Yan and Deng, Hong and Zhang, Qihao and Huang, Yadong and Su, Zhijian and Fu, Yongmei and Xiang, Qi and Zhang, Shu
Steroids, ISSN 0039-128X, 05/2017, Volume 121, pp. 10 - 16
•17β-Hydroxysteroid dehydrogenase type 3 is a potential target for hormone-dependent prostate cancer.•Main characteristics and function of human 17β-HSD3 have... 
Testosterone | Hormone-dependent prostate cancer | Inhibitor | 17β-Hydroxysteroid dehydrogenase type 3 | DEHYDROGENASES | 17 beta-Hydroxysteroid dehydrogenase type 3 | BIOCHEMISTRY & MOLECULAR BIOLOGY | IDENTIFICATION | DEFICIENCY | POTENT | METABOLISM | BIOSYNTHESIS | IN-VIVO | ENDOCRINOLOGY & METABOLISM | INHIBITORS | DERIVATIVES | EXPRESSION | Prostatic Neoplasms - metabolism | Testosterone - metabolism | 17-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Humans | Prostatic Neoplasms - enzymology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - chemistry | 17-Hydroxysteroid Dehydrogenases - metabolism | Prostatic Neoplasms - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Metabolomic profiling of hormone-dependent cancers: a bird's eye view
by Lloyd, Stacy M and Arnold, James and Sreekumar, Arun
Trends in Endocrinology & Metabolism, ISSN 1043-2760, 2015, Volume 26, Issue 9, pp. 477 - 485
Highlights • Hormone-dependent cancers exhibit metabolic reprogramming. • PCa exhibits metabolic alterations in polyamines, amino acids, and fatty acids. • BCa... 
Endocrinology & Metabolism | breast cancer | prostate cancer | therapeutic targets | metabolomics | biomarkers | Biomarkers | Metabolomics | Breast cancer | Prostate cancer | Therapeutic targets | BIOCHEMICAL RECURRENCE | TAMOXIFEN RESISTANCE | RECEPTOR | HUMAN BREAST-CANCER | GLUTAMINE-METABOLISM | ANDROGEN-DEPRIVATION THERAPY | CHOLESTEROL-METABOLISM | MOLECULAR PORTRAITS | EPITHELIAL-CELLS | ENDOCRINOLOGY & METABOLISM | RESISTANT PROSTATE-CANCER | Neoplasms - metabolism | Prostatic Neoplasms - metabolism | Humans | Female | Male | Hormones | Biomarkers, Tumor | Breast Neoplasms - metabolism | Glycine | Fatty acids | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Comorbidities in Australian women with hormone‐dependent breast cancer: a population‐based analysis
by Ng, Huah Shin and Koczwara, Bogda and Roder, David M and Niyonsenga, Theo and Vitry, Agnes I
Medical Journal of Australia, ISSN 0025-729X, 01/2018, Volume 208, Issue 1, pp. 24 - 28
Objective: To compare how frequently selected chronic diseases developed in women with breast cancer receiving endocrine therapy, and in women without cancer.... 
General medicine | Neoplasms | CLINICAL-PRACTICE GUIDELINES | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | THERAPY | PREDICTORS | TOXICITY | AROMATASE INHIBITORS | SURVIVORS | BENEFITS | INDEXES | Depression - epidemiology | Comorbidity | Humans | Middle Aged | Chronic Disease - epidemiology | Breast Neoplasms - drug therapy | Australia - epidemiology | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Chronic Disease - classification | Female | Aged | Retrospective Studies | Cohort Studies | Osteoporosis - epidemiology | Cancer patients | Breast cancer | Diagnosis | Demographic aspects | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Extended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1–97 trial
by Higgins, Michaela J and Liedke, Pedro E.R and Goss, Paul E
Critical Reviews in Oncology and Hematology, ISSN 1040-8428, 2012, Volume 86, Issue 1, pp. 23 - 32
Abstract Early hormone-receptor-positive breast cancer is a chronic relapsing disease that can remain clinically silent for many years. The NCIC-CTG MA.17/BIG... 
Hematology, Oncology and Palliative Medicine | Extended adjuvant endocrine therapy | MA.17 | 2-GENE EXPRESSION RATIO | COST-EFFECTIVENESS | RANDOMIZED-TRIAL | MOLECULAR GRADE INDEX | TAMOXIFEN THERAPY | TO-TREAT ANALYSIS | ONCOLOGY | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | POSTMENOPAUSAL WOMEN | HEMATOLOGY | CARDIOVASCULAR RISK-FACTORS | Nitriles - economics | Triazoles - administration & dosage | Triazoles - adverse effects | Breast Neoplasms - economics | Tamoxifen - economics | Humans | Neoplasms, Hormone-Dependent - economics | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Triazoles - economics | Female | Chemotherapy, Adjuvant - economics | Antineoplastic Agents, Hormonal - economics | Aromatase Inhibitors - administration & dosage | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Breast Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Aromatase Inhibitors - economics | Chemotherapy, Adjuvant - methods | Neoplasms, Hormone-Dependent - drug therapy | Tamoxifen - adverse effects | Nitriles - adverse effects | Breast cancer | Hormones | Tamoxifen | Analysis | Adjuvant treatment | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Role of steroid receptor and coregulator mutations in hormone-dependent cancers
by Groner, Anna C and Brown, Myles
Journal of Clinical Investigation, ISSN 0021-9738, 04/2017, Volume 127, Issue 4, pp. 1126 - 1135
Steroid hormones mediate critical lineage-specific developmental and physiologic responses. They function by binding their cognate receptors, which are... 
BREAST-CANCER | ENDOCRINE RESISTANCE | TRANSCRIPTION FACTORS | MEDICINE, RESEARCH & EXPERIMENTAL | MOLECULAR PORTRAITS | MUTANT ANDROGEN RECEPTORS | ALPHA EXPRESSION | LIGAND-BINDING DOMAIN | RESISTANT PROSTATE-CANCER | TAMOXIFEN-RESISTANCE | ESTROGEN-RECEPTOR | Receptors, Steroid - metabolism | Humans | Male | Signal Transduction - genetics | Neoplasm Proteins - metabolism | Breast Neoplasms - metabolism | Androgens - genetics | Breast Neoplasms - therapy | Prostatic Neoplasms | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Receptors, Steroid - genetics | Estrogens - genetics | Female | Mutation | Androgens - metabolism | Estrogens - metabolism | Neoplasm Proteins - genetics | Receptors | Gene mutations | Oncology, Experimental | Research | Properties | Health aspects | Steroid hormones | Cancer | Disease | Estrogen | Endocrine therapy | Metastasis | Gene expression | Cancer therapies | Androgens | Womens health | Surgery | Epigenetics | Ligands | Prostate | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers
by Rohira, Aarti D and Lonard, David M
Biochemical Pharmacology, ISSN 0006-2952, 09/2017, Volume 140, pp. 1 - 7
[Display omitted] Steroid receptor coactivators (SRCs) are essential regulators of nuclear hormone receptor function. SRCs coactivate transcription mediated by... 
Transcription | Hormone-dependent cancer | Drug development | Coregulator | Steroid receptor coactivator | ANDROGEN RECEPTOR | ACTIVATION | AIB1 | CELL-PROLIFERATION | HISTONE ACETYLTRANSFERASE | TRANSCRIPTIONAL COACTIVATOR | BREAST-CANCER | STRUCTURAL BASIS | ESTROGEN | PHARMACOLOGY & PHARMACY | EXPRESSION | Neoplasms, Hormone-Dependent - metabolism | Drug Resistance, Multiple | Humans | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Nuclear Receptor Coactivator 1 - chemistry | Nuclear Receptor Coactivator 2 - metabolism | Molecular Targeted Therapy | Neoplasm Proteins - metabolism | Neoplasms, Hormone-Dependent - immunology | Nuclear Receptor Coactivator 2 - chemistry | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Nuclear Receptor Coactivator 1 - metabolism | Nuclear Receptor Coactivator 3 - chemistry | Drug Design | Anti-Inflammatory Agents - therapeutic use | Antineoplastic Agents - pharmacology | Protein Interaction Domains and Motifs | Nuclear Receptor Coactivator 3 - antagonists & inhibitors | Nuclear Receptor Coactivator 1 - antagonists & inhibitors | Anti-Inflammatory Agents - pharmacology | Neoplasm Proteins - chemistry | Antineoplastic Agents - chemistry | Anti-Inflammatory Agents - chemistry | Nuclear Receptor Coactivator 2 - antagonists & inhibitors | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Nuclear Receptor Coactivator 3 - metabolism | Ligands | Neoplasms, Hormone-Dependent - drug therapy | Drugs | Medical colleges | Estrogen | DNA binding proteins | Metastasis | Chemotherapy | Epidermal growth factor | Interleukins | Methyltransferases | Pancreatic cancer | Physiological aspects | Progesterone | Drug therapy | Protein binding | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights